User profiles for AP Cope
Andrew CopeProfessor of Rheumatology, King's College London Verified email at kcl.ac.uk Cited by 15192 |
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid …
The Study Group for Risk Factors for Rheumatoid Arthritis was established by the EULAR
Standing Committee on Investigative Rheumatology to facilitate research into the preclinical …
Standing Committee on Investigative Rheumatology to facilitate research into the preclinical …
[PDF][PDF] The central role of T cells in rheumatoid arthritis
AP Cope, H Schulze-Koops… - Clinical and experimental …, 2007 - researchgate.net
… For none of these three approaches is it presently clear how they might affect the function …
COPE AP: Studies of T-cell activation in chronic inflammation. Arthritis Res 2002; 4 (Suppl. 3…
COPE AP: Studies of T-cell activation in chronic inflammation. Arthritis Res 2002; 4 (Suppl. 3…
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
… Andrew P Cope , Andrew P Cope … Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola
Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway, A systematic …
Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway, A systematic …
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells
INTRODUCTION The inflammasomes and the complement system are traditionally viewed
as quintessential components of innate immunity required for the detection and elimination of …
as quintessential components of innate immunity required for the detection and elimination of …
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
… Many biologic activities of TNFa appear to be involved in the pathogenesis of chronic
inflammation and arthritis. Thus, TNFa can induce resorption of cartilage and bone (1,2), …
inflammation and arthritis. Thus, TNFa can induce resorption of cartilage and bone (1,2), …
[HTML][HTML] The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
Background Patients on therapeutic immunosuppressants for immune-mediated inflammatory
diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate …
diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate …
[HTML][HTML] Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation
…, A Ersek, DF Baban, LM Williams, AP Cope… - PloS one, 2012 - journals.plos.org
A major therapeutic challenge is how to replace bone once it is lost. Bone loss is a characteristic
of chronic inflammatory and degenerative diseases such as rheumatoid arthritis and …
of chronic inflammatory and degenerative diseases such as rheumatoid arthritis and …
Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling
… Indeed, repeated injections of adult female NOD mice with anti-TNF significantly increase
the incidence and severity of diabetes compared to control animals (Cope, AP, and HO …
the incidence and severity of diabetes compared to control animals (Cope, AP, and HO …
[HTML][HTML] Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?
…, L Svensson, C Sanchez-Blanco, M Saini, AP Cope - FEBS letters, 2011 - Elsevier
… Our laboratory has also demonstrated the importance of reduced IL-2 production in this
model, in the context of skewed Th cell differentiation (Somenzi and Cope, unpublished data). …
model, in the context of skewed Th cell differentiation (Somenzi and Cope, unpublished data). …
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
…, K Benesova, TRDJ Radstake, AP Cope… - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the …
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the …